Bimekizumab, sold under the brand name Bimzelx (/bɪmˈzɛlɪks/ bim-ZEL-iks), is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody[6][7] that is used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa.
[8] Bimekizumab was approved for medical use in the European Union in August 2021,[6][9][10] and in the United States in October 2023.
[11][12] In November 2024, bimekizumab was approved by the US Food and Drug Administration for the treatment of active moderate-to-severe hidradenitis suppurativa in adults.
[14] Phase III trials have demonstrated that bimekizumab is superior to not only adalimumab[15] but also secukinumab[16] and ustekinumab[17] for the treatment of plaque psoriasis.
The approval for the treatment of active moderate-to-severe hidradenitis suppurativa (HS) in adults was supported by data from two Phase 3 studies, BE HEARD I and BE HEARD II, which evaluated the efficacy and safety of bimekizumab in the treatment of adults with moderate-to-severe HS.